HOME >> MEDICINE >> NEWS
Novel antibiotic provides rapid relief from symptoms of tonsillitis/pharyngitis, study shows

Ketek (telithromycin), a novel compound from a new family of antibiotics, administered once daily for five days to patients suffering from tonsillitis/pharyngitis, provided equivalent clinical and bacteriological outcomes as those observed in patients receiving a 10-day course of treatment with penicillin V, a new study shows.

The more rapid symptom relief achieved with Ketek, the first antibiotic from the ketolide family to be developed for clinical use, may suggest a potential for a faster return to usual activities, and fewer days lost from work or school, for people with tonsillitis/pharyngitis resulting from group A b-haemoliytic streptococcus (GABHS) bacteria. GABHS is the most common bacterial cause of tonsillitis/pharyngitis.

The study results, reported today at the 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Istanbul, Turkey, were among several scientific presentations involving Ketek.

"This is an important study as it demonstrates the clinical and bacteriological effectiveness and symptom relief of Ketek in treating what is a very common upper respiratory tract infection," said Dr. Joanne Chang, Aventis Pharma.

The double-blinded study enrolled 396 patients between the ages of 15 and 65 with clinical signs and symptoms of acute tonsillopharyngitis, and who either had a positive streptococcal A antigen test or a positive throat culture for GABHS. These patients were randomized (198 patients to each group) to receive either 800 mg once daily Ketek followed by placebo for five days, or penicillin V 500 mg three-times daily for 10 days. Clinical and bacteriological outcomes were assessed at post-therapy (days 16-21) and late post-therapy (days 38-45).

At the post-therapy visit, bacteriological outcome was satisfactory in 79.7 percent and 79.3 percent of patients, and clinical cure was achieved in 85.9 percent and 85.8 percent of patients in the Ketek (198 patients) and penicillin V (197
'"/>

Contact: Liz Rickard
elizabeth.rickard@ketchum.com
44-0-20-7611-3633
Ketchum
4-Apr-2001


Page: 1 2

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel drugs help solve Gleevec resistance
5. Novel imaging technique shows abnormal brain anatomy in children with ADHD
6. Novel drug-antidote strategy provides greater control of drug action
7. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
8. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
9. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
10. Novel findings about neovessel formation
11. Novel MRI technique provides clear images of blood flow

Post Your Comments:
(Date:10/30/2014)... By Dennis Thompson ... -- Drinking lots of milk could be bad for your ... that the calcium in milk can help strengthen bones and ... health officials to recommend milk as part of a healthy ... amounts of milk did not protect men or women from ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Eating a low-carb, high-fat ... treat, according to new research. A review ... Atkins diet, that focuses on foods like bacon, eggs, ... reduce seizures in adults whose condition doesn,t improve with ... percent of people with epilepsy whose seizures are not ...
(Date:10/30/2014)... new vaccine that could help prevent some cases of ... Food and Drug Administration on Wednesday. Trumenba is ... and 25 from invasive meningococcal disease caused by ... can infect the bloodstream (sepsis) and the lining that ... leading cause of bacterial meningitis, and infection can occur ...
(Date:10/30/2014)... standard of care for children facing acute myeloid leukemia ... in the latest edition of the New England ... John Wagner, Jr., M.D., director of the Pediatric Blood ... and a researcher in the Masonic Cancer Center, University ... and myelodysplastic syndrome who received transplants of either one ...
(Date:10/29/2014)... 2014 – Many of the women at first acted surprised. ... to researchers why they had not used the study products ... prevention trial that, as a likely consequence, did not find ... effective. , The women were among 127 former VOICE ... D, agreed to take part in in-depth interviews and/or focus ...
Breaking Medicine News(10 mins):Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3
(Date:10/30/2014)... -- Zimmer Holdings, Inc. (NYSE: ZMH and ... and organizational structure of the combined company following the ... the combined organization will leverage the strength of both ... the new brand to be rolled out across the ... future leadership team is committed to establishing Zimmer Biomet ...
(Date:10/30/2014)... Oct. 30, 2014   ViaDerma, Inc. ... bringing new products to market, has recently released ... TetraStem is a topical liquid tetracycline-based antibiotic that ... can convert oral medication active ingredients into topical ... first aid antibiotic to help prevent skin infection ...
(Date:10/30/2014)... SAN FRANCISCO , Oct. 30, 2014  Nektar ... financial results for the third quarter ended September 30, ... of U.S.-based financial markets. Howard Robin , president ... to review the results beginning at 5:00 p.m. Eastern ... The press release and a live audio-only Webcast of ...
Breaking Medicine Technology:Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
Cached News: